Transfection with Livin and Survivin shRNA inhibits the growth and proliferation of non‑small cell lung cancer cells

Huang,Qinmiao; Zeng,Yiming; Lin,Huihuang; Zhang,Huaping; Yang,Dongyong

doi:10.3892/mmr.2017.7490

Transfection with Livin and Survivin shRNA inhibits the growth and proliferation of non‑small cell lung cancer cells

Authors:
- Qinmiao Huang
- Yiming Zeng
- Huihuang Lin
- Huaping Zhang
- Dongyong Yang
View Affiliations

Affiliations: Department of Respiratory Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China
Published online on: September 13, 2017 https://doi.org/10.3892/mmr.2017.7490
Pages: 7086-7091

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is reported to be a major public health issue worldwide and the overall prognosis of patients remains poor. The expression levels of Livin and Survivin, of the inhibitors of apoptosis (IAP) family, are associated with prognostic significance in the majority of solid tumors. Therefore, in the presents study, short hairpin (sh)RNA expression vectors inhibiting the Livin and Survivin genes were constructed to examine the effects of the transfection of Livin shRNA and/or Survivin shRNA on the biological functions of tumor cells. The transfection efficiency was measured using fluorescence reverse transcription‑quantitative polymerase chain reaction and western blot analyses. The cell growth inhibition ratio was measured using a CCK assay. Cell apoptosis following transfection and in tumor tissues were measured using a TUNEL assay, and a cancer xenograft model was used to investigate the effect of Livin shRNA and/or Survivin shRNA on tumor growth. The results indicated that the mRNA and protein expression levels were suppressed following the transfection of Livin and Survivin shRNA into tumor cells (P<0.05, compared with control group). The growth of tumor cells in vivo and in vitro was significantly inhibited following transfection with Livin and Survivin shRNA, compared with that in the other groups (P<0.05). Taken together, the transfection of cells with Livin and Survivin inhibited tumor growth in vivo and in vitro, with the co‑transfection of Livin and Survivin shRNA showing increased efficiency, compared with transfection of either the Livin vector or Survivin vector alone. The combined inhibition of Livin and Survivin may be a promising multitargeted gene therapeutic strategy in cancer treatment.

View Figures

View References

1	Gatti L, Cossa G, Tinelli S, Carenini N, Arrighetti N, Pennati M, Cominetti D, De Cesare M, Zunino F, Zaffaroni N and Perego P: Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment. J Pharmacol Exp Ther. 348:360–371. 2014. View Article : Google Scholar : PubMed/NCBI
2	Janssen-Heijnen ML, van Steenbergen LN, Steyerberg E, Visser O, De Ruysscher DK and Groen HJ: Long-term excess mortality for survivors of non-small cell lung cancer in the Netherlands. J Thorac Oncol. 7:496–502. 2012. View Article : Google Scholar : PubMed/NCBI
3	Chung JH, Choi YS, Cho JH, Kim HK, Kim J, Zo JI and Shim YM: Uniportal video-assisted thoracoscopic lobectomy: An alternative to conventional thoracoscopic lobectomy in lung cancer surgery? Interact Cardiovasc Thorac Surg. 20:813–819. 2015. View Article : Google Scholar : PubMed/NCBI
4	Tacelli N, Santangelo T, Scherpereel A, Duhamel A, Deken V, Klotz E, Cortot A, Lafitte JJ, Wallyn F, Remy J and Remy-Jardin M: Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy. Eur Radiol. 23:2127–2136. 2013. View Article : Google Scholar : PubMed/NCBI
5	Takenaka T, Takenoyama M, Inamasu E, Yoshida T, Toyokawa G, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, Seto T and Ichinose Y: Role of surgical resection for patients with limited disease-small cell lung cancer. Lung Cancer. 88:52–56. 2015. View Article : Google Scholar : PubMed/NCBI
6	Donington JS, Koo CW and Ballas MS: Novel therapies for non-small cell lung cancer. J Thorac Imaging. 26:175–185. 2011. View Article : Google Scholar : PubMed/NCBI
7	Takahashi Y, Yamaoka K, Nishikawa M and Takakura Y: Quantitative and temporal analysis of gene silencing in tumor cells induced by small interfering RNA or short hairpin RNA expressed from plasmid vectors. J Pharm Sci. 98:74–80. 2009. View Article : Google Scholar : PubMed/NCBI
8	Gazzaniga P, Gradilone A, Giuliani L, Gandini O, Silvestri I, Nofroni I, Saccani G, Frati L and Aglianò AM: Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol. 14:85–90. 2003. View Article : Google Scholar : PubMed/NCBI
9	LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S and Korneluk RG: IAP-targeted therapies for cancer. Oncogene. 27:6252–6275. 2008. View Article : Google Scholar : PubMed/NCBI
10	Guan HP, Sun JZ, Feng XL, Chen JS, Chen FJ, Cheng XF, Liu XW and Ni B: Effects of RNA interference-mediated knockdown of livin and survivin using monomethoxypolyethylene glycol-chitosan nanoparticles in MG-63 osteosarcoma cells. Mol Med Rep. 13:1821–1826. 2016. View Article : Google Scholar : PubMed/NCBI
11	Yang AQ, Wang PJ, Huang T, Zhou WL and Landman J: Effects of monomethoxypolyethylene glycol-chitosan nanoparticle-mediated dual silencing of livin and survivin genes in prostate cancer PC-3M cells. Genet Mol Res. 5:2016.doi: 10.4238/gmr.15027430.
12	Yang D, Song X, Zhang J, Ye L, Wang S, Che X, Wang J, Zhang Z, Wang L and Shi W: Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells. Acta Biochim Biophys Sin (Shanghai). 42:137–144. 2010. View Article : Google Scholar : PubMed/NCBI
13	Zhang Y, Huang H, Zhou H, Du T, Zeng L, Cao Y, Chen J, Lai Y, Li J, Wang G and Guo Z: Activation of nuclear factor kB pathway and downstream targets survivin and livin by SHARPIN contributes to the progression and metastasis of prostate cancer. Cancer. 120:3208–3218. 2014. View Article : Google Scholar : PubMed/NCBI
14	McIntyre GJ and Fanning GC: Design and cloning strategies for constructing shRNA expression vectors. BMC Biotechnol. 6:12006. View Article : Google Scholar : PubMed/NCBI
15	Zhao X, Yuan Y, Zhang Z, Feng X, Zhang J, Yuan X and Li J: Effects of shRNA-silenced livin and survivin on lung cancer cell proliferation and apoptosis. J BUON. 19:757–762. 2014.PubMed/NCBI
16	Xu W, Chang H, Qin CK and Zhai YP: Impact of Co-transfection with livin and survivin shRNA expression vectors on biological behavior of HepG2 cells. Asian Pac J Cancer Prev. 14:5467–5472. 2013. View Article : Google Scholar : PubMed/NCBI
17	Kong X, Li L, Sun L, Fu K, Long J, Weng X, Ye X, Liu X, Wang B, Yan S, et al: Rapid diagnosis of aneuploidy using segmental duplication quantitative fluorescent PCR. PLoS One. 9:e889322014. View Article : Google Scholar : PubMed/NCBI
18	Mavridis K, Stravodimos K and Scorilas A: Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem. 59:261–269. 2013. View Article : Google Scholar : PubMed/NCBI
19	Tirrò E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A and Vigneri P: Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res. 66:4263–4272. 2006. View Article : Google Scholar : PubMed/NCBI
20	Spänkuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M and Strebhardt K: Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst. 96:862–872. 2004. View Article : Google Scholar : PubMed/NCBI
21	Custodio A, Méndez M and Provencio M: Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications. Cancer Treat Rev. 38:36–53. 2012. View Article : Google Scholar : PubMed/NCBI
22	van der Drift MA, Karim-Kos HE, Siesling S, Groen HJ, Wouters MW, Coebergh JW, de Vries E and Janssen-Heijnen ML: Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years. J Thorac Oncol. 7:291–298. 2012. View Article : Google Scholar : PubMed/NCBI
23	Mansoori B, Shotorbani S Sandoghchian and Baradaran B: RNA interference and its role in cancer therapy. Adv Pharm Bull. 4:313–321. 2014.PubMed/NCBI